Upslope Capital Management Exited West Pharmaceutical (WST) for Better Opportunities

2 weeks ago 14

Soumya Eswaran

Mon, January 19, 2026 astatine 7:10 AM CST 3 min read

Upslope Capital Management, an concern absorption company, released its fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Upslope aims to supply attractive, equity-like returns portion reducing marketplace hazard and keeping debased correlation with accepted equity strategies. The 4th fourth marked a beardown extremity to an exceptional twelvemonth for the firm. The Fund delivered beardown results with reduced downside risk. The Fund returned +2.0% (net) successful Q4 compared to +1.6% for some the S&P Midcap 400 ETF (MDY) and HFRX Equity Hedge Index. For the twelvemonth 2025, the Fund returned +14.8% compared to +7.2% and +10.1% returns for the indexes, respectively. The steadfast observed that markets are progressively dynamic, and astir concern decisions are driven by aggressive, thematic, and precise short-term-focused strategies. As a closing note, the missive states that identifying concern opportunities is straightforward, but returns stay uncertain fixed the existent economical landscape. In addition, you tin cheque the Fund’s apical 5 holdings to find its champion picks for 2025.

In its fourth-quarter 2025 capitalist letter, Upslope Capital Management highlighted stocks specified arsenic West Pharmaceutical Services, Inc. (NYSE:WST). West Pharmaceutical Services, Inc. (NYSE:WST) designs, manufactures, and sells containment and transportation systems for injectable drugs and healthcare products. The one-month instrumentality for West Pharmaceutical Services, Inc. (NYSE:WST) was -5.49%, and its shares mislaid 22.76% implicit the past 52 weeks. On January 16, 2026, West Pharmaceutical Services, Inc. (NYSE:WST) banal closed astatine $259.79 per share, with a marketplace capitalization of $18.69 billion.

Upslope Capital Management stated the pursuing regarding West Pharmaceutical Services, Inc. (NYSE:WST) successful its 4th fourth 2025 capitalist letter:

"The Fund besides exited West Pharmaceutical Services, Inc. (NYSE:WST) (WST, shaper of packaging/components for injectable cause transportation devices). This was owed to amended perceived risk/reward for existing and caller components of the Fund’s healthcare “basket” (which includes: STERIS, Bio-Rad, and precocious added Henry Schein)."

KeyBanc Sees Injectable GLP-1s Driving Ongoing Demand for WST

West Pharmaceutical Services, Inc. (NYSE:WST) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 49 hedge money portfolios held West Pharmaceutical Services, Inc. (NYSE:WST) astatine the extremity of the 3rd quarter, which was 46 successful the erstwhile quarter. In Q3 2025, West Pharmaceutical Services, Inc. (NYSE:WST) reported revenues of $805 million, marking an summation of 5% connected an integrated basis. While we admit the imaginable of West Pharmaceutical Services, Inc. (NYSE:WST) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.